ITHIN THE LAST 5 YEARS, two major findings have advanced our knowledge of the biology of human multiple myeloma (MM). First, somatic mutations without intraclonal variation have been detected in Ig genes of tumor plasma cells.'" This finding indicates that the major oncogenic events yielding to a continuous proliferation of the tumor stem cell occur in a cell selected through antigen contact in lymphoid follicles. Secondly, interleukin-6 (IL-6) has been identified as a major cytokine involved in the emergence of the tumor clone and in tumor-associated toxicities in patients with MM.4-6 These findings relate MM biology to recent knowledge of B-cell imm~nopoiesis~~~ and to IL-6, IL-6 receptors, and IL-6-mediated transduction signals. ' The purpose of this review was to provide a critical analysis of the literature addressing the role of IL-6 in MM as compared with that in the generation of normal plasma cells.
GENERATION OF NORMAL PLASMA CELLS WITHIN BONE MARROW (BM)
Bone marrow is the main production site in humans for antigen-specific Igs,"' accounting for about 60% of serum IgG and IgA and 20% of serum IgM." As reviewed elsewhere',' and illustrated in Fig 1, BM plasma cells derive from plasmablastic cells generated in peripheral lymphoid organs after antigen stimulation. This process requires at least three steps: (1) differentiation of centrocytic B cells into low-rate Ig-secreting plasmablastic cells and migration to BM, (2) proliferation of these immature plasmablastic cells in the BM, and (3) differentiation of BM plasmablastic cells into high-rate Ig-secreting plasma cells. These different steps have been clearly identified using human T-cell activation-dependent methodology.'' Among the factors controlling the differentiation of centrocytic cells into plasmablastic cells, CD40 activation is critical, at least in CD40-and Tcell-dependent ~y s t e m s . '~"~ Soluble CD23 and IL-la may also induce centrocytic cells to differentiate into plasmablastic cells (Fig l) .'7 Most cytokines with "B-cell growth factor activity" in vitro, including IL-2, IL-4, and IL-10, are also able to induce partial differentiation of B cells into plasma cells secreting Ig.7 IL-10 is the most potent B-cell differentiation factor, inducing complete differentiation of B cells into mature plasma cells in association with CD40 a~tivati0n.l~ It is also the main cytokine responsible for B-cell differentiation in the EL-4 T-cell-dependent system of Werner Favre et al. ' 5 IL-10 is a switch factor inducing IgD+ B cells to produce IgG1-and IgG3-secreting plasma cells." IL-6 alone is not able to induce Ig production from Staphylococcus Aureus Cowan (SAC)-or anti-Ig-stimulated purified B cells, but potentiates the effect of IL-2, probably by further induction of plasma cell differentiation, as discussed be-OW.^^^'"' IL-6 was first identified as an inducer of Ig secretion in the Epstein-Barr virus (EBV)-infected CESS lymphoblastoid cell line.''-23 However, a recent study has emphasized that this effect was not caused by a specific activation of Ig gene but by an overall activation of cell growth-related genesz4 Thus, it has not yet been proven that IL-6 is a true differentiation factor inducing normal B cells to differentiate into plasma cells. Nor has the contrary been proven. Indeed, it is noteworthy that autocrine IL-6 is produced by CD40-and IL-10-stimulated B cells or SAC-stimulated B cells and that this autocrine IL-6 may participate in the differentiation of B cells into plasma cell^.^,^' Autocrine production of IL-6 may also occur in the T-cell-dependent system mentioned above.'' Involvement of autocrine IL-6 as a true B-cell differentiation factor has been suggested by observations in patients with IgM monoclonal gammopathy of undetermined significance. Purified B cells from these patients spontaneously differentiate into plasma cells, but such differentiation is blocked by anti-IL-6 antibodiesz5 or by retinoic acid, which inhibits the autocrine IL-6 produced by these cells.2h
FACTORS CONTROLLING THE PROLIFERATION OF NORMAL PLASMABLASTIC CELLS
The concept of early proliferating plasmablastic cells is not commonly recognized but has been clearly demonstrated in two in vitro B-cell differentiation systems (T-cell or Pokeweed mitogen activati~n''~~~) as well as in the BM of patients with reactive plasmacytosis." Presently, only IL-6 has been shown to be involved in the proliferation of these normal z plasmablastic cells. Indeed, an anti-IL-6 antibody was found to suppress plasmablastic cell proliferation in patients with reactive polyclonal plasmacytosis (Fig l) .29 In addition, mice bearing an IL-6 transgene driven by the Ep promoter developed massive oligoclonal plasmacytosis and died within 7 weeks3' When crossed with Balb/c mice that have a genetic background for developing plasmacytomas, these IL-6 transgenic mice developed monoclonal plasmacytomas."
FACTORS CONTROLLING THE DIFFERENTIATION OF NORMAL PLASMABLASTIC CELLS INTO MATURE PLASMA CELLS
In the T-cell activation system, IL-6 is the only cytokine able to replace stimulated T cells to induce the development of plasmablastic cells into mature plasma cells.'* The major role of IL-6 in controlling Ig production by nondividing mature plasma cells has also been determined using BM mononuclear BM cells) is responsible for the production of two thirds of serum IgG and IgA." These nondividing cells are able to produce high amounts of Ig spontaneously in vitro (>600 pg/cell/24 h), and IL-6 together with VLA-4 activation control this production.33 Finally, the major role of IL-6 in the generation of plasma cells producing antigenspecific antibodies in mucosa has been demonstrated in IL-6 knockout mice. These mice have a major defect in generating antigen-specific antibodies in mucosa that can be reversed by the addition of IL-6.34.3s Although IL-10 also induces the generation of mature plasma cells in the CD40 systern,13 it is not clear whether this cytokine acts directly on mature plasma cells because autocrine IL-6 production is found in this culture system. cells.'2.3' Indeed, a minor population (0.01% to 0.1% of 
IL-6 I S A MAJOR GROWTH FACTOR FOR MYELOMA CELLS IN VITRO
The presence of somatic mutations in Ig genes of malignant plasma cells implies that the tumor stem cell (ie, capable of self-renewal) is either a memory B cell or a plasmablastic cell. As noted above, the proliferatiotddifferentiation factors and proliferation sites of these two cells are different (Fig  1) . IL-2, E-4, IL-10, and eventually IL-6 are the main proliferatioddifferentiation factors for B cells in lymphoid follicles, whereas IL-6 is the only identified proliferation factor of plasmablastic cells in BM.
In patients with MM, myeloma cells proliferate and accumulate in BM in close proximity to stromal and hematopoietic cells (myeloid, monocytic, fibroblast, bone cells, etc). When BM cells from these patients are cultured for several days, spontaneous myeloma cell proliferation is observed in about half the cases: actually those with detectable proliferating myeloma cells in vivo.36 In patients lacking such cells (patients with inactive disease), the plasmablastic compartment is too small to be detected in vivo. Many cytokines are produced in short-term cultures of tumor samples, including IL-6," granulocyte-macrophage colony-stimulating factor (GM-CSF),37 granulocyte-CSF (G-CSF; Klein, personal communication), IL-l1 (Klein, personal communication), IL-l,38.39 tumor necrosis factor (TNF),4 and probably others. All these cytokines contribute to spontaneous myeloma cell p r~l i f e r a t i o n~.~~.~~ (Klein, personal communication) . However, the fact that the addition of anti-IL-6 monoclonal antibodies (MoAbs) inhibits proliferation almost completely is a clear and simple indication that IL-6 is an essential myeloma cell growth factor in v i t r~?~~~~~' We studied 30 patients with active disease, including 14 with plasma-cell leu- Previous studies have shown a lack of correlation between labeling with Ki67 and antibromodeoxyuridine antibodie~.~' This is understandable because nonproliferating myeloma cells are in a stimulated stage, expressing high levels of c-myc proteins2 and p21"s.53 Secondly, myeloma cells were quantified by morphology, which is not a relevant approach for studying the minor fraction of highly proliferating plasmablastic cells.54 Finally, such methodologies using correlations with several samples are very poor compared with previous studies in which endogenous IL-6 was neutralized on myeloma cells to show its growth factor activlarge numbers of plasma cells from peripheral blood cells of MM patients initially devoid of plasma cells and cultured with IL-3 and IL-6.55 However, these results were not confirmed by three or by us (B. Klein, personal communication).
The fact that IL-6 makes possible to reproducibly obtain malignant plasmablastic cell lines whose growth is completely dependent on addition of exogenous IL-6 offers further evidence of the major role of this cytokine as a malignant plasmablastic growth f a~t o r .~~.~' These cell lines, which have a plasmablastic phenotype and cytology, were extremely difficult to obtain before the availability of recombinant IL-6 and were mostly autonomously growing lines. However, IL-6-dependent myeloma cell lines can be obtained only from patients with terminal disease and extramedullary proliferation, which suggests that additional events are required for long-term culture of plasmablastic cells from patients with chronic disease. Thus, these findings indicate that IL-6 is a major growth factor of proliferating malignant plasmablastic cells in vitro, probably because this cytokine is a major growth factor for their normal counterPart.
IL-6 IS NOT A DIFFERENTIATION FACTOR FOR MYELOMA CELLS
All pertinent studies indicate that myeloma cells produce much lower amounts of Ig than do fully mature normal plasma cells in BM (Table 1) . Moreover, the addition of IL-6 or anti-IL-6 antibodies does not modulate their Ig producof myeloma cell differentiation into high-rate Ig-secreting mature plasma cells, a process normally controlled by IL-6 ( Fig 1 and Table 1 ). This might be caused by an abnormality in IL-6-mediated signal transduction in myeloma cells (see below). In a study referred to above,50 the Ig production rate was used as a differentiation parameter to argue that IL-6 is a differentiation factor for myeloma cells. No direct demonstration was provided relative to previous studies showing a lack of IL-6 differentiation effect on malignant plasma cell^^'.^' or a major differentiation effect on normal plasma Moreover, the rates for Ig production of undifferentiated versus so-called differentiated myeloma cells were so low in this study (3 v 7 pg/cell/24 h) as compared with those of mature normal plasma cells (100 to 5,000 pg/ce11/24 h) that it is unwarranted to employ the term "differentiated myeloma cells." In fact, what is most striking in this study (as in other studies) is the immature stage of myeloma cells and the inability of IL-6 to fulfill its differentiation role as in normal plasma cells. tion~41,4S,S0,61-6S Clearly, one major MM abnormality is a lack
IL-6 IS A PARACRINE RATHER THAN AN AUTOCRINE MYELOMA CELL GROWTH FACTOR IN VIVO
Whether IL-6 is an autocrine (produced by tumor cells themselves) or a paracrine (produced by the tumor environment) myeloma cell growth factor is still controversial in For personal use only. on July 26, 2017. by guest www.bloodjournal.org From 1994. This is surprising because suitable experimental studies (without obvious experimental artifacts) have sustained the paracrine hypothesis, and there is currently no solid evidence for a deregulated IL-6 production in myeloma cells that could result in their continuous proliferatioddifferentiation. The autocrine hypothesis was initially proposed by Kawan0 et a1,6 who only showed that populations enriched in myeloma cells (but still containing nonmyeloma cells) produced a small amount of IL-6 in comparison with the huge amounts produced by the tumor en~ironment.~ The autocrine hypothesis has been put forward once again in a recent study claiming that no IL-6 production in myeloma cells was initially detected by immunochemistry, enzymelinked immunosorbent assay (ELISA) spot, or in situ hybridization.hh To detect such production, the investigators had to sort myeloma cells on the basis of CD38 and/or CD45 expression and the very sensitive polymerase chain reaction (PCR) technique that was capable of detecting 1 positive cell out of IOh cells in this study.6h It is concluded that immature myeloma cells produce IL-6 that could serve as an autocrine proliferation/differentiation factor." Actually, several obvious artifacts may explain these findings and rule out the investigators' conclusion. First, CD38 and CD45 antigens are activation antigens.'j7 In particular, activation of CD38 antigen induces strong IL-6 production in T cells.67 It is thus likely that the triggering of these antigens by antibodies would result in activation of several genes whose expression could be detected by the very sensitive PCR technique. Secondly, it is known that some cells are very high IL-6 producers. For example, two monocytes are able to produce 1 pg of IL-6 per 24 hours,6x which is the amount produced by 2 X lo4 purified myeloma cells in the study in question. 66 Therefore, the contamination of myeloma cells by only one or two cells could account for this endogenous IL-6 production. Thirdly, the most obvious argument is that exogenous IL-6 can induce the expression of its own gene through activation of nuclear factors such as NF-IL-6.69
Consequently, once myeloma cells are exposed to exogenous IL-6, some nonconstitutive activation of their IL-6 gene could occur and be detected by PCR analysis. The only serious argument for the autocrine hypothesis is the existence of the autonomously growing U266 myeloma cell line that produces IL-6 as an autocrine growth f a~t o r .~" .~'
However, this autocrine IL-6-producing cell line, as shown by Nilsson et al," was generated as a result of secondary in vitro mutations. Indeed, proliferation of the original U266 cell line, obtained in 1970 and still available, is absolutely dependent on the addition of exogenous IL-6.44
Thus, there is currently no solid evidence that deregulated IL-6 gene expression occurs in myeloma cells in vivo and results in their deregulated proliferatioddifferentiation. On the contrary, the paracrine hypothesis has been proven by three lines of evidence: ( l ) myeloma cell lines, which are completely dependent on exogenous IL-6 for their proliferamal cells from patients with MM produce higher amounts of IL-6 than do stromal cells from healthy individuals after trigerring with myeloma ~e l l s .~' .~~ These data emphasize that the survival, proliferation, and differentiation of the myeloma stem cell in patients with MM is probably dependent on close contact with stromal cells similar to murine plasm a c y t o m a~.~~ Feeder-cell-dependent plasmacytoma cell lines have been obtained in this model. Although IL-6 is an essential growth factor for these murine plasmacytoma cell lines, additional factors, including adhesion of tumor cells to feeder cells, are necessary for tumor growth.7s As human MM appears to be very similar to these models, it is quite likely that human myeloma cells produce cytokines or express adhesion molecules inducing the BM environment to produce IL-6.7'.74 One of these cytokines is IL-IP. Several investigators have indicated that populations enriched in myeloma cells produce IL-IP,3x.'9 and antibodies to IL-I or IL-1 receptor antagonist have inhibited endogenous IL-6 production in short-term cultures of BM cells from patients with MM" (Klein, unpublished results). Other cytokines such as CSF-I, which is produced by myeloma cells,7h or TNF might also be involved, although their role remains unclear.
IL-6 IS LIKELY TO BE A MYELOMA CELL GROWTH FACTOR IN VIVO
In the preceding sections, we reviewed the literature showing that IL-6 is a major growth factor for freshly explanted human myeloma cells in vitro, that it is produced by the BM environment, and that exogenous IL-6-dependent myeloma cell lines can be reproducibly obtained from patients with extramedullary proliferation. In addition, we and others have shown that this cytokine is overproduced in vivo in association with a poor p r o g n o~i s .~~,~~ For these reasons, we treated patients with terminal disease with anti-IL-6 MoAb. Detailed results in one patient have been previously published.' Results in another 10 patients have been submitted for publication. In some patients, anti-IL-6 MoAb inhibited myeloma cell proliferation, induced a decrease in tumor cell mass, and reduced tumor-associated toxicities (fever, bone pain, and cachexia). Further biologic studies have indicated that these antitumoral effects are found only in patients in whom overall IL-6 production in vivo is not too high to be neutralized by anti-IL-6 MoAb (unpublished results). In other patients, mean IL-6 production was estimated to be about 10-fold greater than the maximum that could be neutralized. This poor inhibitory effect of anti-IL-6 MoAb can be attributed to its ability to stabilize IL-6 in the form of stable monomeric immune complexes having a 3-to 4-day half-life in vivo." The injection of an antibody combination recognizing different epitopes on the IL-6 molecule may solve this problem. In fact, we have shown that the resulting polymeric immune complexes have a very short half-life in vivo (< 1 hour) compared with monomeric ones.*" tion -and do not produce IL-6, can be obtained reproducibly from every patient with extramedullary pr~liferation~~.~"; (2) IL-6 mRNA is expressed significantly by BM cells from 
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IL-6 first binds IL-6R, with an affinity of mom, and the IL-6/IL-6R complex then binds the p 1 3 0 transducer, with a resulting affinity of 10"' mom. A remarkable feature of IL-6 receptor is the agonist role of the soluble form of IL-6R (sIL-6R, 55 kD MW) that is able to bind IL-6 with an affinity almost like that of membrane ILdR. Moreover, the IL-6/sIL-6R complex is able to bind and activate the gp130 transducer chain.82 A similar property has recently been reported for soluble receptor of ciliary neurotrophic factor (CNTF), another cytokine using the same transducer g 1 3 0 chain as IL-6.83 Thus, these two soluble receptors (sIL-6R and sCNTFR), unlike all previously known soluble receptors with antagonist properties (sTNFR, sIL-lR, sIL-~R, sIL-4R, sIFN-yR, etc), are the only ones with an agonist effect. Soluble IL-6R may be generated by the shedding of membrane IL-6RM as well as by translation of an alternative spliced RNA. 85 Increased and high levels of sIL-6R are found in the plasma of patients with MM as compared with age-related healthy individuals (mean values, 200 v 80 ng/mL)."j It has been determined that soluble ILdR is a powerful prognostic factor because patients with high levels have a poor progn~sis.'~ Similarly to recombinant sIL-~R, purified plasma sIL-6R plays an agonist role because at physiologic concentrations it can produce a 10-fold increase in the IL-6 sensitivity of myeloma cell linesE6 During a 2-year follow-up of 15 patients treated by autologous BM transplantation, we found that plasma sIL-6R levels were highly stable and independent of tumor cell mass.86 This observation was puzzling because we had no reason to expect that in vivo production of sIL-6R by malignant plasma cells would be low compared with that of hepatocytes and dermal cells, the main IL-6-binding cells in vivo. 88 We first found that sIL-6R production by malignant plasma cells was similar to that of human hepatocyte cell lines in vitro (1 to 5 ng of sIL-6R per day and per lo6 cells) and then that the mass of malignant plasma cells was probably of the same order of magnitude as that of hepatocytes and dermal cells in vivo. This observation suggests that plasma sIL-6R level is regulated by a tumor-independent mechanism in vivo, eventually at a genetic level. In fact, plasma sa-6R levels are dramatically increased in mice strains susceptible to autoimmune diseases and plasma~ytomas?~ In healthy individuals, plasma IL-6 is undetectable ( < l pghL). In patients with MM, plasma IL-6 concentration has been found to average 30 pg/mL." Because plasma sIL-6R concentrations are greater than the kd of the molecule, more than half the circulating IL-6 is bound to sIL-~R, and the IL-6/sIL-6R complex should activate cells expressing membrane gp130, ie, almost every cell in vivo. Thus, certain inhibitors should prevent these cells from being activated. One such inhibitor is plasma-soluble gp130. In fact, recombinant-soluble gp130 has been shown to bind the IL-6IsIL-6R complex.g0 Moreover, we found a high concentration of sgpl30 in the plasma of MM patients and that purified sgp 130 inhibited proliferation of IL-6-dependent myeloma cell lines (unpublished observation).
OTHER IN VITRO MYELOMA CELL GROWTH FACTORS ARE RELATED TO IL-6 OR THE gp130 IL-6 TRANSDUCER
Cytokines using the gp130 transducer chain. Four cytokines were recently found to use the same transducer chain as IL-6: CNTF, IL-11, leukemia inhibitory factor (LIF), and oncostatin M (OSM).91*92 These cytokines share the major functions of IL-6. Interestingly, they are also growth factors for myeloma cell lines and, in fact, IL-11 -or LIF-or OSMdependent myeloma cell lines have been obtained. 93 The responsiveness or unresponsiveness of myeloma cell lines to LIF, OSM, and CNTF is associated with the expression or lack of expression of LIF receptor (gp190) on myeloma cells.93 Furthermore, a recent study found that LIF and OSM stimulated the proliferation of fresh myeloma cells obtained from a patient with plasma cell leukemia," whereas IL-11 failed to stimulate the proliferation of freshly explanted myeloma cells, corroborating a previous report95 and our unpublished results.
We used a sensitive bioassay for IL-1196 to detect low amounts of IL-11 (30 to 150 pg/mL) in culture supernatants of BM cells from some patients with MM, whereas no LIF was detected (<25 pg/mL) in the same culture supernatants (B. Klein, unpublished results). No detectable LIF or IL-11 was found in the plasma of 100 patients with MM or plasma cell leukemia (unpublished results). Thus, it is not presently clear whether these cytokines are growth factors for tumor cells in vivo (at least in a subset of patients). Nonetheless, it should be noted that these cytokines are produced by bone cells (LIF and IL-11). For example, the SAOS2 osteoblastic cell line constitutively produces IL-l1 but not IL-6.96 Because myeloma cells proliferate in close proximity to bone cells, some of these cytokines may be important, at least in a subset of patients with MM.
G-CSF. G-CSF is a hematopoietic cytokine with a gene structurally homologous with the IL-6 gene.97 G-CSF receptor is a dimer of two gp130 chains that shares strong homologies with gp130 IL-6 transducer:8 and the signalling events induced by G-CSF receptor are related to those induced by the gp130 IL-6 transducer.w In particular, both G-CSF and IL-6 induce activation of NF-IL-6 nuclear fact0r.6~ G-CSF is a growth factor for freshly explanted myeloma cells and we obtained a sensitive myeloma cell line for G-CSF.'" The fact that the myeloma cell growth factor activity of G-CSF is abrogated by anti-IL-6 and anti-IL-6R antibodies indicates that it is mediated by IL-6. However, no control of endogenous IL-6 production or any increase in IL-6 receptor expression by G-CSF has been found. One possible explanation is that G-CSF cooperates with IL-6 at the level of signaling proteins. G-CSF is probably involved in the physiopathology of MM in vivo. Indeed, the G-CSF gene is expressed in tumor samples in vivo,"' and G-CSF is found in the plasma of most patients with MM. Moreover, in one patient we found that treatment with recombinant G-CSF (1 pg/kg/d) for 7 days in the absence of any associated therapy led to a dramatic increase in tumor proliferation in vivo.'" These data suggest that G-CSF should be used with due caution when the intention is to accelerate hematopoietic recovery in MM or improve the yield of hematopoietic stem cells, as indicated in three recent case reports.loz""
Interferon-a (IFN-a) . IFN-a was shown to stimulate the proliferation and growth of most IL-6-dependent myeloma cell lines.60s105 We showed that IFN-a stimulates the growth of these lines by inducing autocrine production of IL-6 in For personal use only. on July 26, 2017. by guest www.bloodjournal.org From p53 MAP kinases myeloma cells. allowing IFN-a-dependent myeloma cell lines to be obtained." '5 Interestingly. autonomously growing cell lines producing their own IL-6 as an autocrine growth factor can be established very quickly (within several weeks) from these IFN-a-dependent cell lines. This may explain why most myeloma cell lines reported in the literature are autonomously growing ones and why some. such as the U266 cell line, produce IL-6 as an autocrine growth facAs noted above, the original U266 cell line was dependent on addition of exogenous IL-6 for its proliferation.JJ Concerning freshly explanted myeloma cells, four studies report that IFN-a stimulated the tumoral proliferation from 16% to 30% of patients at diagnosis and 50% of treated patients. In the other patients. IFN-(Y had either no effect or on the contrary an inhibitory One report indicates that IFN-a inhibited the production of the monoclonal Ig without affecting myeloma cell proliferation in vitro.IwJ This stimulatory or inhibitory effect of IFN-a on the proliferation of fresh myeloma cells from different patients might explain its controversial clinical efficacy as a maintenance treatment in this disease.""'"' An initial in vitro screening of its stimulatory or inhibitory activity on patients' myeloma cells before treatment might help to clarify this controversy.
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MM IS A gp130 IL-6 TRANSDUCER-RELATED DISEASE
This review has shown that at least seven cytokines are growth factors for malignant plasmablastic cells in vitro: five cytokines stimulating the gpl30 IL-6 transducer (IL-6, LIF, OSM, IL-I 1. and CNTF); G-CSF, which acts through IL-6-related mechanisms and activates a transducer chain closely related to the IL-6 transducer; and IFNa, which induces autocrine production of IL-6 in myeloma cells (Fig 2) .
The fact that the spontaneous proliferation of freshly explanted myeloma cells is almost totally inhibited by anti-IL-6 antibodies indicates that IL-6 is the major myeloma cell growth factor in vitro. This may be explained simply by the fact that the concentration of bioactive IL-6 in the culture supernatants of tumor samples is much greater (500-to 5.000-fold higher) than that of other myeloma cell growth factors. Cytokine concentrations in tumor samples in vivo are more difficult to estimate because of their diffusion and circulation. However. large concentrations ( I to 50 ng/mL) of IL-6 were found in closed tumor samples such as pleural effusions or ascites, whereas LIF and IL-l 1 were undetectable (unpublished observations) and OSM and CNTF were not searched for. This situation may also explain why IL-6 is a major myeloma cell growth factor in vivo, as suggested by treatments with anti-lL-6 antibodies. However. it cannot be excluded that LIF, OSM, IL-l I , or CNTF may be the dominant myeloma cell growth factor in vivo in some patients.
All these results indicate that activation of the gpl30 IL-6 transducer is a key signal for inducing myeloma cell proliferation. The gpl30-mediated transduction signal is now better understood.' First of all, it involves activation of Jak-Tik kinases and lyn kinase by homodimerization or heterodimerization of gp130, phosphorylation of the Stat family of transcription factors (APRF and ISGF3a), activation of p21"" and the MAP kinase cascade, and phosphorylation of various transcription factors by these kinases. A membrane proximal cytoplasmic domain of 60 amino acids appears to be sufficient for dimerization of gp130 for Jak-Tik kinase activation and resulting activation of the MAP kinase cascade.".' Similar mechanisms have been found for the gpl30 G-CSF transducer that is quite homologous with the gp130 IL-6 transd~cer.~*"' For this receptor, a proliferation signal, but not a differentiation signal, is associated with MAP kinase activation.Il4 As noted above, IL-6 is a proliferation factor for normal early plasmablastic cells and a differentiation factor for their maturation into plasmacytic cells (Fig l ) . Myeloma cells are in an immature stage of plasma cell differentiation, and IL-6 is unable to induce their further maturation. By analogy with the G-CSF transduction signal, mutations in the gp130 transducer chain or in proteins involved in the signalling cascade stimulated by gp130 might be important oncogenic events leading to this blockade of malignant plasmablastic cell differentiation. For example, ras genes are frequently mutated in patients with fulminant disease."'.'Ih Recently, a mutated ras protein has been shown to increase the MAP kinase cascade induced by gp130 activation,"' which might be associated with proliferation and not differentiation as in the case of the gp130 G-CSF transdu~er"~ (Fig 2) . Moreover, we recently found mutations in the cytoplasmic domain of gp130 in some tumor samples."x Further studies of the gpl30-mediated transduction signal should be of considerable help in improving our knowledge of MM biology.
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INHIBITORS OF IL-6 AND gp130 IL-6 TRANSDUCER AS TREATMENTS FOR PATIENTS WITH MM
There are many means of inhibiting L -6 and IL-6-related cytokines: blockage of cytokine production, neutralization of cytokine activity, inhibition of cytokine receptor, and inhibition of signal transduction. Corticosteroids strongly inhibit inflammatory cytokine production by blocking gene trans~ription,"~ which may account for the potent antitumoral activity of dexamethasone in MM.'" Estrogen also inhibits IL-6 production and might be of clinical interest.'" Finally, we noted here that several cytokines and adhesion molecules control the activation of the tumor environment to produce IL-6. Inhibitors of these cytokines, such as L -1 receptor antagonist or TNF binding protein, are now available for clinical use and should be investigated in patients with MM. Treatments with anti-IL-6 MoAb have shown that the production of C-reactive protein is completely controlled by IL-6 in vivo. 5 The monitoring of this protein should be very useful in evaluating the clinical efficacy of various inhibitors of IL-6 production. As noted above, it is difficult to neutralize IL-6 activity because of its high production in vivo. In one patient who developed sepsis during anti-IL-6 MoAb treatment, total L 6 production was estimated to be greater than 7 mg/d,"* whereas, in other patients, total IL-6 production ranged from 2 to 350 pg/d. The administration of a single anti-IL-6 MoAb is apparently insufficient because of IL-6 stabilization in the form of monomeric c~mplexes.'~ The simultaneous injection of different anti-L-6 MoAbs might solve this problem. Recently, an IL-6 receptor antagonist was reported to inhibit IL-6 activity when present at a concentration 100-to 1,000-fold higher than that of IL-6.'23 Our estimations indicate that at least 35 to 350 mgld of L-6 receptor antagonist should be injected in some patients to neutralize IL-6 production. The inhibition of IL-6R or gp130 transducer chain by antibodies or other antagonists would appear to be difficult. Indeed very large levels of sIL-6R or sgpl30 circulate in plasma, and IL-6R and gp130 are present on many cells. 
